A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
Abstract
Phase 3 placebo-controlled trial of obeticholic acid in patients with PBC who had inadequate response to or unacceptable side effects with UDCA.
Overview
CoChat Summary
TL;DR
In the 12-month POISE phase 3 trial, obeticholic acid added to ursodiol or given as monotherapy improved the composite biochemical primary end point in patients with primary biliary cholangitis compared with placebo. Obeticholic acid also increased pruritus and serious adverse events.
Key findings
- The primary composite end point occurred in 46% of the 5–10-mg group and 47% of the 10-mg group versus 10% of the placebo group (P<0.001 for both comparisons).
- Alkaline phosphatase decreased by least-squares mean −113 U/L in the 5–10-mg group and −130 U/L in the 10-mg group versus −14 U/L with placebo (P<0.001 for both); total bilirubin changed by −0.02 and −0.05 mg/dL versus +0.12 mg/dL, respectively (P<0.001 for both).
- Noninvasive measures of liver fibrosis did not differ significantly between either obeticholic acid group and placebo at 12 months.
- Pruritus occurred in 56% of the 5–10-mg group and 68% of the 10-mg group versus 38% with placebo; serious adverse events occurred in 16%, 11%, and 4%, respectively.
Methods
- Randomized, double-blind, placebo-controlled, parallel-group, 12-month phase 3 trial at 59 sites in 13 countries; 217 patients underwent randomization and 216 received at least one dose, assigned 1:1:1 to placebo, obeticholic acid 5 mg with adjustment to 10 mg if applicable, or obeticholic acid 10 mg.
- Patients had primary biliary cholangitis with inadequate response to ursodiol or unacceptable ursodiol side effects; 93% received ursodiol as background therapy.
- Primary end point: alkaline phosphatase <1.67× upper limit of normal with ≥15% reduction from baseline and normal total bilirubin at 12 months; analyzed in the intention-to-treat population with Cochran–Mantel–Haenszel testing stratified by randomization factors, with missing values counted as nonresponse.
Limitations
- The paper states that results cover only 2 years of treatment, that the trial focused on surrogate biomarkers, imaging, and symptom end points with no statistical power to assess clinical outcomes, and that multiplicity adjustments were made only for the primary end point and not for secondary or exploratory analyses.
- Evident from the text: the open-label extension was not placebo-controlled, so longer-term durability and crossover findings are uncontrolled.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 12 Not checked · 78 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
What the sources say
- Not checked — no full text of the sourcecites [13] source
- Disputedcites [14] sourceExperimental — accuracy not yet measured
The Discussion’s Systematic review says FXR agonists have indirect anti-fibrotic effects in animal models, contrary to the claim of direct anti-fibrotic effects. The cited passages do not describe direct anti-inflammatory effects or identify such pathways; page numbers are unavailable in our copy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [15] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two 12-week phase 2 studies, daily doses of up to 50 mg of obeticholic acid resulted in reductions from baseline in levels of alkaline phosphatase and bilirubin that were significantly greater than those with placebo. 16”
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Abstract and Primary Efficacy End Point section report one three-month placebo-controlled trial in which daily obeticholic acid doses of 10–50 mg significantly reduced alkaline phosphatase versus placebo. The Secondary End Points section reports lower median conjugated bilirubin with obeticholic acid, but does not state that this reduction was statistically significant versus placebo. This paper therefore does not support the claim about two studies or the stated significance for bilirubin. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, dose-related increases in the incidence and severity of pruritus were evident, particularly at doses of more than 10 mg.”
What the sources say
- Supportedcites [16] source
The Adverse Events section says both pruritus incidence and severity were worse in the 25-mg and 50-mg groups than at 10 mg. It reports severe pruritus in 16%, 24%, and 37% of patients at 10, 25, and 50 mg, respectively. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a large, international cohort analysis involving patients with primary biliary cholangitis, elevations in the alkaline phosphatase level were independently associated with a risk of liver transplantation or death that was 2.0 to 2.5 times as high as the risk associated with normal levels. 10”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (p. 3) says the analyses adjusted for age, sex, year of diagnosis, and UDCA therapy. The Results (p. 4) find higher alkaline phosphatase associated with greater risk of transplantation or death, but compare patients above 2.0 times the upper limit of normal with those at or below that threshold—not specifically with patients whose alkaline phosphatase was normal. The cited passages do not establish the claimed 2.0-to-2.5-fold risk relative to normal levels. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the subgroup of patients who had transient elastography assessed (43%), obeticholic acid was not associated with significant reductions in this noninvasive measure of liver fibrosis at 12 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an intention-to-treat analysis, biochemical response was met in 10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-titrated OCA groups, respectively (p \0.0001 for both).”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue is not related to severity of liver disease, with the exception of very end-stage patients where it is the norm [221], and it is not responsive to UDCA or OCA therapy [6,131].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, OCA was not effective in decreasing PBC-induced liver fibrosis21,22.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
44 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 3×
“(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
BackgroundPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citation
Research works printed but not linked: 1
- Bolier AR, 2012, Acta Gastroenterol Belg, 75, 399
Cited by
Items 501–600 of 1,138
Emerging drugs for the treatment of primary sclerosing cholangitis
Abbas, N., Quraishi, M. N., & Trivedi, P. J. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.003 · Cited by 17
Recent advances in the treatment of primary sclerosing cholangitis
Bjornsson, E. S., & Kalaitzakis, E. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1860751 · Cited by 19
Xu, Y., Zhao, Z., Yan, E. P., Lian, Z., & Zhang, W. (2023) · Medicine Advances · doi:10.1002/med4.23 · Cited by 19
Li, X., Hu, L., Chu, H., Chen, L., Yan, J., Wang, W., Yang, X., Zhu, Q., Du, F., Song, Y., et al. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00398 · Cited by 22
Parés, A. R. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.009 · Cited by 24
Emerging treatments for primary sclerosing cholangitis
Rodríguez, E. A., Carey, E. J., & Lindor, K. D. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1293524 · Cited by 17
“Given its proven efficacy in the treatment of other cholestatic diseases such as primary biliary cholangitis (PBC), UDCA was studied and fount to have biological plausibility in the treatment of PSC.”
BackgroundInfluentialSelf-citationChau, M., Li, Y., Roqueta‐Rivera, M., Garlick, K., Shen, R., Wang, G., Or, Y. S., & Jiang, L. (2019) · International Journal of Gastroenterology · doi:10.11648/j.ijg.20190301.12 · Cited by 17
“In recent clinical trials in patients with NASH, as well as healthy volunteers, OCA caused significant dyslipidemia with elevated low density lipoprotein (LDL) cholesterol and reduced high density lipoprotein (HDL) cholesterol [4-7].”
BackgroundTian, S., Hu, Y., Zhang, M., Wang, K., Guo, G., Li, B., Shang, Y., & Han, Y. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03163-y · Cited by 17
“67 × upper limit of normal (ULN) and bilirubin < 1 × ULN) to distinguish high- or low-risk patients [31].”
BackgroundEpigenetics of Primary Biliary Cholangitis
Li, Y., Tang, R., & Ma, X. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3449-2_10 · Cited by 14
Gut Microbiome and Bile Acid Interactions
Wu, N., Bayatpour, S., Hylemon, P. B., Aseem, S. O., Brindley, P. J., & Zhou, H. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.11.004 · Cited by 17
Microbiome and Cardiovascular Disease
Herrema, H., Nieuwdorp, M., & Groen, A. K. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_356 · Cited by 18
Fousekis, F. S., Mpakogiannis, K. C., Lianos, G. D., Antonelli, E., Bassotti, G., & Katsanos, K. H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217817 · Cited by 23
Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review
Mago, S., & Wu, G. Y. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00036 · Cited by 21
“There was also an increased dose-dependent incidence of pruritis noted among patients treated with OCA in comparison to those not treated.(53) Research regarding the use of fibrates, which affects bile acid homeostasis due to the activation of peroxisome proliferator activator receptor (PPAR), has yielded promising da…”
ResultInfluentialPrimary biliary cholangitis and the narrowing gap towards optimal disease control
Cançado, G. G. L., Lleò, A., Levy, C., Trauner, M., & Hirschfield, G. M. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00025-1 · Cited by 24
Self-citationLiver Fibrosis: A Clinical Update
Shipley, L. C., Axley, P. D., & Singal, A. K. (2019) · EMJ Hepatology · doi:10.33590/emjhepatol/10313576 · Cited by 24
Bile Salt and FGF19 Signaling in the Early Phase of Human Liver Regeneration
Koelfat, K. V. K., van Mierlo, K. M. C., Lodewick, T. M., Bloemen, J. G., van der Kroft, G., Amygdalos, I., Neumann, U. P., Dejong, C. H. C., Jansen, P. L. M., Damink, S. W. M. O., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1728 · Cited by 19
Azizsoltani, A., Niknam, B., Taghizadeh-Teymorloei, M., Ghoodjani, E., Dianat-Moghadam, H., & Alizadeh, E. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118249 · Cited by 15
Hvistendahl, M., Naimi, R. M., Hansen, S. H., Rehfeld, J. F., Kissow, H., Pedersen, J., Dragsted, L. O., Sonne, D. P., Knop, F. K., & Jeppesen, P. B. (2021) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2224 · Cited by 18
Góméz, E., Montero, J. L., Molina, E., García-Buey, L., Casado, M., Fuentes, J., Simón, M. Á., Díaz‐González, Á., Jorquera, F., Morillas, R. M., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18004 · Cited by 15
“12 Additionally, fenofibrate, a predominant PPAR-α agonist and bezafibrate, a pan-PPAR agonist, have anti-cholestatic properties.”
BackgroundInfluentialNuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica
Ampuero, J., Sanchez-Torrijos, Y. M., Aguilera, V., Bellido, F., & Romero‐Gómez, M. (2017) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2017.07.006 · Cited by 20
Wetten, A., Jones, D. E. J., & Dyson, J. K. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2130750 · Cited by 17
“Importantly, OCA increases serum low-density lipoprotein (LDL), with small corresponding decreases in high-density lipoprotein [12,27,28]; these changes are likely a consequence of downregulation of the rate-limiting enzyme, cytochrome P450 (CYP) 7A1 by OCA, which leads to a reduction in the conversion of cholesterol…”
BackgroundMethodSelf-citationHvas, C. L., Ott, P., Paine, P., Lal, S., Jørgensen, S. P., & Dahlerup, J. F. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i21.2320 · Cited by 16
Primary Biliary Cholangitis — A New Name and a New Treatment
Pratt, D. S. (2016) · New England Journal of Medicine · doi:10.1056/nejme1607744 · Cited by 20
Expression of unfolded protein response genes in post-transplantation liver biopsies
Liu, X., Taylor, S. A., Celaj, S., Levitsky, J., & Green, R. M. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02459-8 · Cited by 15
“67 × upper limit of normal [15]; and (4) NR: others with non-HBR high LFTs (NR:Others) if there was no histologic evidence of acute rejection, but serum ALT, AST and ALP levels were > 1.”
BackgroundYoshida, E. M., Mason, A. L., Peltekian, K. M., Shah, H., Thiele, S. L., Borrelli, R., & Fischer, A. (2018) · CMAJ Open · doi:10.9778/cmajo.20180029 · Cited by 15
Self-citationJang, H.-J., Han, N., Staatz, C. E., Kwak, J., & Baek, I. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102227 · Cited by 17
Kimura, M., Ogawa, E., Harada, K., Imamura, J., Saio, M., Ikura, Y., Yatsuhashi, H., Murata, K., Miura, K., Ieiri, I., et al. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2022-001001 · Cited by 15
Carbone, M., Gerussi, A., Cardinale, V., Cazzagon, N., Cossiga, V., Lleò, A., Marrone, G., Marzioni, M., Moschetta, A., Muratori, L., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.05.002 · Cited by 18
Zhao, Y. M., Zhao, W., Bu, H., Toshiyoshi, M., & Zhao, Y. (2023) · Medicine · doi:10.1097/md.0000000000032892 · Cited by 17
Shan, D., Dai, S., Chen, Q., Xie, Y., & Hu, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1218432 · Cited by 16
Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia
Eastern Slovakia PBC Group, Dražilová, S., Babinská, I., Gazda, J., Halánová, M., Janíčko, M., Kucinsky, B., Šafčák, D., Martinkova, D., Tarbajova, L., et al. (2020) · International Journal of Public Health · doi:10.1007/s00038-020-01391-6 · Cited by 20
Research Progress on the Pharmacological Action of Schisantherin A
Xiao, Z., Xiao, W., & Li, G. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6420865 · Cited by 20
Danford, C. J., Ezaz, G. Z., Trivedi, H. D., Tapper, E. B., & Bonder, A. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.05.003 · Cited by 16
Current and promising therapy for primary biliary cholangitis
Gossard, A. A., & Lindor, K. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601701 · Cited by 16
“For those who received 10 mg per day, 47% reached the primary end point [27].”
BackgroundSelf-citationMorel, C., Chowdhary, V., Nagesh, P. T., Ribeiro, M. D. C., Hawryluk, D., Catalano, D., Adorini, L., & Szabó, G. (2022) · Liver International · doi:10.1111/liv.15374 · Cited by 17
Cançado, G. G. L., Couto, C. A., Terrabuio, D. R. B., Cançado, E. L. R., Villela‐Nogueira, C. A., Ferraz, M. L. G., Braga, M. H., Nardelli, M. J., Faria, L. C., Gomes, N. M. D. F., et al. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07654-x · Cited by 15
Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases
Saha, P., & Hartmann, P. (2025) · Microorganisms · doi:10.3390/microorganisms13061188 · Cited by 16
“Obeticholic acid has been trialed in several CLDs, including PBC [202–204], MASLD [205,206], and PSC [207].”
Obeticholic Acid in Primary Biliary Cholangitis
Jindal, A., Gupta, A., & Sarin, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1611913 · Cited by 12
Self-citationKimura, N., Takamura, M., Takeda, N., Watanabe, Y., Arao, Y., Takatsuna, M., Takeuchi, S., Abé, H., Setsu, T., Kamimura, H., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10163-0 · Cited by 16
“Besides UDCA, obeticholic acid [10] and bezafibrate [11, 12] are currently available and effective for patients with PBC.”
BackgroundMedical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Karlsen, T. H., Jørgensen, K. K., & Bergquist, A. M. (2024) · Hepatology · doi:10.1097/hep.0000000000001172 · Cited by 19
“…with OCA in PBC was based on results from the POISE trial, a phase III, randomized, double-blind placebo-controlled study which demonstrated a significant, sustained reduction in ALP, [128] and its inclusion criteria and endpoints set standards for further trials in PBC (the POISE criteria).”
Agrawal, R. (2019) · Annals of Gastroenterology · doi:10.20524/aog.2019.0403 · Cited by 17
Comeglio, P., Filippi, S., Sarchielli, E., Morelli, A., Cellai, I., Corno, C., Adorini, L., Vannelli, G. B., Maggi, M., & Vignozzi, L. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-1009-2 · Cited by 18
The molecular insights of bile acid homeostasis in host diseases
Zhang, J., Lü, A., & Wang, C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121919 · Cited by 15
New insights into gut-liver axis in advanced liver diseases: A promising therapeutic target
Xing, Y., Ou, Y., Wang, Y., Hou, L., & Zhu, J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117284 · Cited by 13
Qian, J., Yao, T.-T., Wang, Y., & Wang, G. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.03.026 · Cited by 15
Palmer, M., Kleiner, D. E., Goodman, Z. D., Brunt, E. M., Avigan, M., Regev, A., Hayashi, P. H., Lewis, J. H., Mehta, R., Harrison, S. A., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17762 · Cited by 13
Primary Biliary Cholangitis: A Brief Overview
Louie, J. S., Grandhe, S., Matsukuma, K. E., & Bowlus, C. L. (2020) · Clinical Liver Disease · doi:10.1002/cld.867 · Cited by 15
Self-citationManesis, E. K., Schina, M., Vafiadis, I., Gatos, I., Theotokas, J., Zoumpoulis, P. S., Drazinos, P., Ketikoglou, J., Delladetsima, I. K., & TINIAKOS, D. G. (2021) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.1928277 · Cited by 16
An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis
Burman, B. E., Jhaveri, M. A., & Kowdley, K. V. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.06.005 · Cited by 13
Self-citationKanda, T., Sasaki, R., Kimura, N., Abé, H., Yoshida, T., Hayashi, K., Sakamaki, A., Yokoo, T., Kamimura, H., Tsuchiya, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051883 · Cited by 22
“Phase 3 clinical trials demonstrated that obeticholic acid, administered with ursodiol or as monotherapy for 12 months in PBC patients, resulted in decreases from baseline in alkaline phosphatase and total bilirubin levels compared with placebo groups [56].”
Secondary bile acids and the biliary epithelia: The good and the bad
Lenci, I., Milana, M., Signorello, A., Grassi, G. B., & Baiocchi, L. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.357 · Cited by 15
Mulcahy, V., Liaskou, E., Martín, J., Kotagiri, P., Badrock, J., Jones, R. L., Rushbrook, S., Ryder, S. D., Thorburn, D., Taylor-Robinson, S. D., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000110 · Cited by 14
“[18] Controls were age and sex-matched healthy volunteers.”
BackgroundSelf-citationSaeedian, B., Babajani, N., Bagheri, T., Shirmard, F. O., & Pourfaraji, S. M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03821-2 · Cited by 15
“OCA has been shown to successfully decrease ALP and bilirubin levels in patients with PBC [49, 50].”
Tewari, R., Yang, S. J., McClain, E. D., Hu, A. K., Mortensen, E., DeSchmidt, A. M., Chen, J., Kancharla, A., Singh, A. K., James, E. A., et al. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103327 · Cited by 18
Lv, X., Wang, R.-H., Liu, X., Ye, Y.-J., Liu, X.-Y., Qiao, J., & Wang, G. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110051 · Cited by 13
Gene Therapy for Acquired and Genetic Cholestasis
Martínez-García, J., Molina, A., González‐Aseguinolaza, G., Weber, N. D., & Smerdou, C. (2022) · Biomedicines · doi:10.3390/biomedicines10061238 · Cited by 15
“OCA (INT-747/Ocaliva) PBC Phase II Phase III NCT00570765 NCT01473524 Intercept Pharmaceuticals [44,45,72,73] PSC Phase II NCT02177136”
BackgroundImproving prognosis in primary biliary cholangitis – Therapeutic options and strategy
Harms, M. H., van Buuren, H. R., & van der Meer, A. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.004 · Cited by 18
Sayıner, M., Stepanova, M., de Avila, L., Golabi, P., Racila, A., & Younossi, Z. M. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05786-1 · Cited by 14
Fu, K., Li, Y., Dai, S., & Li, Y. (2023) · Nutrients · doi:10.3390/nu15092065 · Cited by 13
“Obechoic acid (OCA) can be used in non-responders of UDCA, but more clinical evidence is needed to reveal the safety and efficacy of this new therapeutic drug [6,7].”
BackgroundPterostilbene Alleviates Cholestasis by Promoting SIRT1 Activity in Hepatocytes and Macrophages
Ma, C., Xiang, J., Huang, G., Zhao, Y., Wang, X., Wu, H., Jiang, K., Liang, Z., Kang, L., Yang, G., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.785403 · Cited by 14
“C chemokine receptor type-2; CLD, cholestatic liver disease; DDC, 3,5-diethoxycarbonyl-1,4dihydrocollidine; FXR, farnesoid X receptor; IL-1β, interleukin 1 beta; LPS, lipopolysaccharide; OCA, obeticholic acid; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; TBA, total bile acids; UDCA, ursodeoxy…”
BackgroundInfluentialLi, Y., Lei, R., Lei, H., Qin, X., Xie, F., Yao, C., & Feng, P. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002471 · Cited by 15
Farnesoid X receptor and bile acids regulate vitamin A storage
Saeed, A., Yang, J., Heegsma, J., Groen, A. K., van Mil, S. W. C., Paulusma, C. C., Zhou, L., Wang, B., & Faber, K. N. (2019) · Scientific Reports · doi:10.1038/s41598-019-55988-w · Cited by 13
Essential updates 2018/2019: Liver transplantation
Ohira, M., Tanimine, N., Kobayashi, T., & Ohdan, H. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12321 · Cited by 12
Li, R., Hovingh, M. V., Koehorst, M., de Blaauw, P., Verkade, H. J., de Boer, J. F., & Kuipers, F. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159163 · Cited by 12
Matsumoto, K., Hirohara, J., Takeuchi, A., Miura, R., Asaoka, Y., Nakano, T., & Tanaka, A. (2023) · Hepatology Research · doi:10.1111/hepr.13931 · Cited by 12
Yang, Y., Zhao, R. C., & Zhang, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.933565 · Cited by 13
“is usually terminated due to adverse effects such as pruritus, which occur in 10% of the patients (Beuers et al., 2015b; Nevens et al., 2016).”
BackgroundWiegand, J., Franke, A., Müller, T., Stein, K., Bantel, H., Günther, R., Denk, G., Reuken, P. A., Schattenberg, J. M., Naumann, U., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2382-7720 · Cited by 12
Xu, Z., Tang, W., Xie, Q., Cao, X., Zhang, M., Zhang, X., & Chai, J. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113781 · Cited by 13
Trends in liver transplantation for autoimmune liver diseases: a Canadian study
Perez, C. F. M., Ivanics, T., Claasen, M. P. A. W., Yoon, P. D., Wallace, D., Selzner, N., Hirschfield, G. M., Hansen, B. E., & Sapisochín, G. (2022) · Canadian Journal of Surgery · doi:10.1503/cjs.012121 · Cited by 13
Self-citationXiang, X., Xiao-li, Y., Shen, M., Huang, C., Liu, Y., Fan, X., & Yang, L. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/6691425 · Cited by 13
Ferrigno, A., Pasqua, L. G. D., Berardo, C., Siciliano, V., Rizzo, V., Adorini, L., Richelmi, P., & Vairetti, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191430 · Cited by 11
Yuan, Z., Wang, J., Zhang, H., Miao, Y., Tang, Q., Yuan, Z., Nong, C., Duan, Z., Zhang, L., Jiang, Z., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1032722 · Cited by 12
Ferrigno, A., Palladini, G., Pasqua, L. G. D., Berardo, C., Richelmi, P., Cadamuro, M., Fabris, L., Perlini, S., Adorini, L., & Vairetti, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238543 · Cited by 13
Farnesoid X receptor: a potential therapeutic target in multiple organs.
Zhang, C., Wang, Z., Feng, Q., Chen, W., & Wang, Y. (2020) · PubMed · doi:10.14670/hh-18-301 · Cited by 19
“However, the adverse events represented by pruritus were serious (Nevens et al., 2016; Kowdley et al., 2018).”
Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead
Chen, Y., Chen, R., Li, H., & Shuai, Z. (2025) · Immunologic Research · doi:10.1007/s12026-025-09622-9 · Cited by 14
Mawardi, M., Alalwan, A. M., Fallatah, H. I., Abaalkhail, F. A., Hasosah, M. Y., Shagrani, M. A., Alghamdi, M., & Alghamdi, A. (2021) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_112_21 · Cited by 14
“The two most recent key trials of second‐line therapy in PBC applied either the revised Toronto criteria (POISE) or the Paris‐2 criteria for selecting high‐risk patients.[46,47]”
BackgroundMethodInfluentialInvolvement of Autophagy in Ageing and Chronic Cholestatic Diseases
Pinto, C., Ninfole, E., Benedetti, A., Marzioni, M., & Maroni, L. (2021) · Cells · doi:10.3390/cells10102772 · Cited by 13
Guan, L., & Miao, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173616 · Cited by 12
Targeting bile salt homeostasis in biliary diseases
Trampert, D. C., Kunst, R. F., & van de Graaf, S. F. J. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000997 · Cited by 12
Mitogen-Activated Protein Kinase and Nuclear Hormone Receptor Crosstalk in Cancer Immunotherapy
Burgermeister, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713661 · Cited by 14
“Recently, the semi-synthetic agonist obeticholic acid (OCA) has been appreciated in phase 3 clinical trials to ameliorate fibrosis in patients with non-alcoholic steatohepatitis [182] and primary biliary cholangitis [183].”
BackgroundIno, H., Endo, A., Wakamatsu, A., Ogura, H., Numachi, Y., & Kendrick, S. F. W. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.576 · Cited by 12
Cost of illness of Primary Biliary Cholangitis - a population-based study
Gerussi, A., Restelli, U., Croce, D., Bonfanti, M., Invernizzi, P., & Carbone, M. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.07.029 · Cited by 14
Self-citationCanovai, E., Farré, R., Accarie, A., Lauriola, M., Hertogh, G. D., Vanuytsel, T., Pirenne, J., & Ceulemans, L. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914881 · Cited by 13
“FXR agonists have been studied in human trials in conditions such as primary biliary cholangitis, primary sclerosing cholangitis, and non-alcoholic steatohepatitis, which have shown encouraging results and good safety profiles [22,35].”
BackgroundManagement of Fatigue in Primary Biliary Cholangitis
Khanna, A., Hegade, V. S., & Jones, D. E. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00458-0 · Cited by 11
Self-citationWang, J., Yuan, Z., Zhang, H., Wu, Q., Miao, Y., Xu, Y., Yu, Q., Huang, X., Zhang, Z., Huang, X., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120882 · Cited by 13
Li, X., Liao, M., Pan, Q., Xie, Q., Yang, H., Peng, Y. H., Li, Q., Qu, J., & Chai, J. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001785 · Cited by 13
Vincentis, A. D., Ampuero, J., Terracciani, F., D’Amato, D., Gerussi, A., Cristoferi, L., Cazzagon, N., Bonaiuto, E., Floreani, A., Calvaruso, V., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.008 · Cited by 13
Self-citationXiao, Y., Wang, W., Peng, S., Lu, Y., Du, J., & Cai, W. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176334 · Cited by 12
Fu, K., Dai, S., Li, Y., Ma, C., Xue, X., Zhang, S., Wang, C., Zhou, H., Zhang, Y., & Li, Y. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166822 · Cited by 12
Lytvyak, E., Hosamani, I. R., Montaño‐Loza, A. J., Saxinger, L. M., & Mason, A. L. (2019) · Canadian Liver Journal · doi:10.3138/canlivj.2018-0020 · Cited by 11
Khanna, A., Jopson, L., Howel, D., Bryant, A., Blamire, A. M., Newton, J. L., Wilkinson, J. S., Steel, A. J., Bainbridge, J., Stefanetti, R. J., et al. (2018) · Efficacy and Mechanism Evaluation · doi:10.3310/eme05020 · Cited by 14
“unselected patient approaches.(14) The RITPBC trial used an unselected approach that may be a limitation.”
BackgroundMethodInfluentialSelf-citationJones, B. A., Myakala, K., Guha, M., et al. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00292.2023 · Cited by 11
The Inconvenient Truth of Primary Biliary Cholangitis/Autoimmune Hepatitis Overlap Syndrome
Hussain, N., & Trivedi, P. J. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.007 · Cited by 16
Structural Basis of Novel Bile Acid-Based Modulators of FXR
Kydd-Sinclair, D., Packer, G., Weymouth‐Wilson, A., & Watson, K. A. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169383 · Cited by 11
Current Treatment Options for Primary Biliary Cholangitis
Wong, K. A., Bahar, R., Liu, C. H., & Bowlus, C. L. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.003 · Cited by 11
Self-citationde Veer, R. C., van Hooff, M. C., da Silva, G., Harms, M. H., Metselaar, H. J., Willemse, J., Utomo, E., & van der Meer, A. J. (2023) · Hepatology Research · doi:10.1111/hepr.13880 · Cited by 13
“The objective need for additional therapy was determined by the POISE criteria.(13) Patients with an ALP >1.”
MethodObeticholic Acid—A Pharmacological and Clinical Review
Keshvani, C., Kopel, J. J., & Goyal, H. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010017 · Cited by 12
“examined the longer-term effectiveness, safety, and adverse events of 5–10 mg OCA in patients with PBC [51].”
BackgroundMethodInfluentialA perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection
Batiha, G. E., Al-Kuraishy, H. M., Al-Gareeb, A. I., Youssef, F. S., El-Sherbeni, S. A., & Negm, W. A. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01111-x · Cited by 11
Wang, T., Tian, T., Zhu, Z., Fang, S., Zhang, L., Peng, X., Shi, R., Li, Y., Wu, J.-S., & Ma, Y. (2024) · Phytotherapy Research · doi:10.1002/ptr.8326 · Cited by 11
“However, prolonged use of OCA may cause side effects such as pruritus and fatigue (Nevens et al. 2016).”
Yu, J., Zhao, C., Zhao, P., Mu, M., Li, X., Zheng, J., & Sun, X. (2024) · iScience · doi:10.1016/j.isci.2024.109118 · Cited by 11
Metadata
- Authors
- Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., Trauner, M., Jones, D. E., Floreani, A., Hohenester, S., Luketic, V., Shiffman, M., van Erpecum, K. J., Vargas, V., Vincent, C., Hirschfield, G. M., Shah, H., Hansen, B., Lindor, K. D., Marschall, H.-U., Kowdley, K. V., Hooshmand-Rad, R., Marmon, T., Sheeron, S., Pencek, R., MacConell, L., Pruzanski, M., & Shapiro, D.
- Affiliations
- University of Padua (IT)
- Humanitas University (IT)
- University Health Network (CA)
- ORCID
- Nevens, Frederik
- Mazzella, Giuseppe
- Strasser, Simone I.
- Bowlus, Christopher
- Invernizzi, Pietro
- Drenth, Joost P.H.
- Pockros, Paul J.
- Beuers, Ulrich
- Trauner, Michael
- Jones, David E.
- Floreani, Annarosa
- Hohenester, Simon
- Luketic, Velimir
- Shiffman, Mitchell
- Vincent, Catherine
- Hirschfield, Gideon M.
- Shah, Hemant
- Hansen, Bettina
- Lindor, Keith D.
- Marschall, Hanns-Ulrich
- Kowdley, Kris V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-18
- Volume
- 375
- Issue
- 7
- Pages
- 631-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2518389324
- Cited by
- 1,131
- References
- 33
- Citations by year
- 2026: 91 · 2025: 118 · 2024: 108 · 2023: 100 · 2022: 123 · 2021: 115 · 2020: 123 · 2019: 111 · 2018: 129 · 2017: 97 · 2016: 14
- FWCI
- 84.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Intercept Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, ursodeoxycholic acid, alkaline phosphatase, total bilirubin, liver fibrosis, pruritus, liver transplantation, liver cirrhosis, drug safety, dose comparison, noninvasive fibrosis assessment
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bile Acids and Salts, Chenodeoxycholic Acid, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.